engleski

Clinical usefulness of longitudinal follow-up of tumor marker CYFRA 21-1 in NSCLC

Lung cancer incidence constantly rises. Croatia is in the second plac in Europe concerning lung cancer mortality. The early detection of local relapse of lung cancer and early application of therapy are essential for the improvement of lung cancer treatment. The aim of this study was early recognition of local relapse of non-small cell lung cancer (NSCLC) by longitudinal follow-up of tumor marker CYFRA 21-1. The sample includes 684 NSCLC patients (419 squamous cell carcinoma nad 265 adenocarcinoma) from stage A to IIIa who have been longitudinally follow-up by the level of CYFRA 21-1 36 to 42 months after surgery. The patients who suffered from relapse received chemotherapy and irradiation. Evaluation of therapy has been made both clinically and using tumor marker level. Serum levels of CYFRA 21-1 were measured using electrochemiluminescence immunoassay on the fully automated Elecsys 2010 system (Roche Diagnostics). Statistical analysis included univariate and multivariate analysis. Following surgical treatment the level of CYFRA 21-1 decreased into the reference range of healthy population, depending on therapy and TNM stage. Comparison between the tumor marker CYFRA 21-1 and standard clinical techniques reveals that CYFRA 21-1 predicts local relapse up to one year before standard methods (p=0.0001). Patients who had CYFRA 21-1 level before therapy above the maximum of the healthy population suffered from local relapse earlier and had a shorter survival period. In conclusion, teh level of tumormarker CYFRA 21-1 above the maximum of the healthy population is a biological signal of an early stage of lung cancer. CYFRA 21-1 is a clinically useful diagnostic and prognostic parameter in NSCLC.

CYFRA 21-1; tumor marker; NSCLC

nije evidentirano